Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

View/ Open
Author
Novobrantseva, Tatiana I
Borodovsky, Anna
Wong, Jamie
Klebanov, Boris
Zafari, Mohammad
Yucius, Kristina
Querbes, William
Ge, Pei
Ruda, Vera M.
Milstein, Stuart
Speciner, Lauren
Duncan, Rick
Barros, Scott
Basha, Genc
Cullis, Pieter
Akinc, Akin
Donahoe, Jessica S
Narayanannair Jayaprakash, K
Jayaraman, Muthusamy
Bogorad, Roman L
Love, Kevin
Whitehead, Katie
Levins, Chris
Manoharan, Muthiah
de Fougerolles, Antonin
Koteliansky, Victor
Published Version
https://doi.org/10.1038/mtna.2011.3Metadata
Show full item recordCitation
Novobrantseva, Tatiana I, Anna Borodovsky, Jamie Wong, Boris Klebanov, Mohammad Zafari, Kristina Yucius, William Querbes, Pei Ge, Vera M Ruda, Stuart Milstein, Lauren Speciner, Rick Duncan, Scott Barros, Genc Basha, Pieter Cullis, Akin Akinc, Jessica S Donahoe, K Narayanannair Jayaprakash, Muthusamy Jayaraman, Roman L Bogorad, Kevin Love, Katie Whitehead, Chris Levins, Muthiah Manoharan, Filip K Swirski, Ralph Weissleder, Robert Langer, Daniel G Anderson, Antonin de Fougerolles, Matthias Nahrendorf, and Victor Koteliansky. 2012. Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Molecular Therapy-Nucleic Acids 1(1): e4.Abstract
Leukocytes are central regulators of inflammation and the target cells of therapies for key diseases, including autoimmune, cardiovascular, and malignant disorders. Efficient in vivo delivery of small interfering RNA (siRNA) to immune cells could thus enable novel treatment strategies with broad applicability. In this report, we develop systemic delivery methods of siRNA encapsulated in lipid nanoparticles (LNP) for durable and potent in vivo RNA interference (RNAi)-mediated silencing in myeloid cells. This work provides the first demonstration of siRNA-mediated silencing in myeloid cell types of nonhuman primates (NHPs) and establishes the feasibility of targeting multiple gene targets in rodent myeloid cells. The therapeutic potential of these formulations was demonstrated using siRNA targeting tumor necrosis factor-α (TNFα) which induced substantial attenuation of disease progression comparable to a potent antibody treatment in a mouse model of rheumatoid arthritis (RA). In summary, we demonstrate a broadly applicable and therapeutically relevant platform for silencing disease genes in immune cells.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381593/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10445630
Collections
- HMS Scholarly Articles [15665]
Contact administrator regarding this item (to report mistakes or request changes)